363 related articles for article (PubMed ID: 25676041)
1. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
Schaffert H; Pelz A; Saxena A; Losen M; Meisel A; Thiel A; Kohler S
Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
[TBL] [Abstract][Full Text] [Related]
2. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis.
Milani M; Ostlie N; Wu H; Wang W; Conti-Fine BM
J Neuroimmunol; 2006 Oct; 179(1-2):152-62. PubMed ID: 16945426
[TBL] [Abstract][Full Text] [Related]
4. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
5. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
Lobito AA; Yang B; Lopes MF; Miagkov A; Adams RN; Palardy GR; Johnson MM; McFarland HI; Recher M; Drachman DB; Lenardo MJ
Eur J Immunol; 2002 Jul; 32(7):2055-67. PubMed ID: 12115627
[TBL] [Abstract][Full Text] [Related]
7. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
8. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
9. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
[TBL] [Abstract][Full Text] [Related]
10. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
Aricha R; Mizrachi K; Fuchs S; Souroujon MC
J Autoimmun; 2011 Mar; 36(2):135-41. PubMed ID: 21193288
[TBL] [Abstract][Full Text] [Related]
11. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
12. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
13. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
14. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.
Aricha R; Feferman T; Scott HS; Souroujon MC; Berrih-Aknin S; Fuchs S
J Autoimmun; 2011 Feb; 36(1):16-24. PubMed ID: 21035305
[TBL] [Abstract][Full Text] [Related]
15. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
16. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice.
Ostlie N; Milani M; Wang W; Okita D; Conti-Fine BM
J Immunol; 2003 Jan; 170(1):604-12. PubMed ID: 12496449
[TBL] [Abstract][Full Text] [Related]
17. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
19. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Maruta T; Oshima M; Mosier DR; Atassi MZ
Autoimmunity; 2017 Aug; 50(5):293-305. PubMed ID: 28548588
[TBL] [Abstract][Full Text] [Related]
20. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.
Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
J Clin Invest; 1997 Dec; 100(12):3027-35. PubMed ID: 9399949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]